546 related articles for article (PubMed ID: 9794562)
1. Iron supplementation in haemodialysis--practical clinical guidelines.
Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
[TBL] [Abstract][Full Text] [Related]
2. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients.
Chuang CL; Liu RS; Wei YH; Huang TP; Tarng DC
Nephrol Dial Transplant; 2003 Feb; 18(2):370-7. PubMed ID: 12543894
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
Dittrich E; Schillinger M; Sunder-Plassmann G; Hörl WH; Vychytil A
Perit Dial Int; 2002; 22(1):60-6. PubMed ID: 11929146
[TBL] [Abstract][Full Text] [Related]
4. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
5. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
6. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
7. Influence of intravenous iron therapy on novel markers of iron deficiency.
Chinnappa S; Bhandari S
Int J Artif Organs; 2010 May; 33(5):297-301. PubMed ID: 20593351
[TBL] [Abstract][Full Text] [Related]
8. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
9. Experience with zinc protoporphyrin as a marker of endogenous iron availability in chronic haemodialysis patients.
Baldus M; Salopek S; Möller M; Schliesser J; Klooker P; Reddig J; Gansert U; Brass H
Nephrol Dial Transplant; 1996 Mar; 11(3):486-91. PubMed ID: 8710158
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T
Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737
[TBL] [Abstract][Full Text] [Related]
11. [Indications and practical management of parenteral iron therapy].
Kosch M; Schaefer RM
Wien Klin Wochenschr; 2003 Jun; 115(11):380-4. PubMed ID: 12879735
[TBL] [Abstract][Full Text] [Related]
12. Rapid recurrence of IBD-associated anemia and iron deficiency after intravenous iron sucrose and erythropoietin treatment.
Kulnigg S; Teischinger L; Dejaco C; Waldhör T; Gasche C
Am J Gastroenterol; 2009 Jun; 104(6):1460-7. PubMed ID: 19491860
[TBL] [Abstract][Full Text] [Related]
13. Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients.
Sepandj F; Jindal K; West M; Hirsch D
Nephrol Dial Transplant; 1996 Feb; 11(2):319-22. PubMed ID: 8671786
[TBL] [Abstract][Full Text] [Related]
14. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
15. Effects of proactive iron and erythropoiesis-stimulating agent protocol implementation on achieving clinical guideline targets for anaemia in a satellite haemodialysis patient cohort.
Yong K; Kairaitis L
Nephrology (Carlton); 2010 Apr; 15(3):288-93. PubMed ID: 20470296
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
[TBL] [Abstract][Full Text] [Related]
17. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron.
Trivedi HS; Brooks BJ
Am J Nephrol; 2003; 23(2):78-85. PubMed ID: 12481145
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder.
Geisser P; Rumyantsev V
Arzneimittelforschung; 2010; 60(6a):373-85. PubMed ID: 20648929
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
Bielesz B; Lorenz M; Monteforte R; Prikoszovich T; Gabriel M; Wolzt M; Gleiss A; Hörl WH; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1512-1521. PubMed ID: 34470831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]